DexCom Profile



Odds of Distress

Check how we calculate scores
Equity ratings for DexCom are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting August 16, 2019 and ending today November 14, 2019. Click here to learn more.
Fiscal Quarter End: December 31, 2019   Follow

DexCom Profile

Next fiscal quarter end is expected on December 31, 2019. The stock is currently experiencing buyout trend. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. DexCom operates under Medical Laboratories Research classification in USA and is traded on BATS Exchange. It employs 2800 people. more
DexCom Fama & French Medical Equipment
Medical Equipment
Fama & French Classification
DexCom SEC Filings
DexCom SEC Filings
Security & Exchange Commission EDGAR ReportsView All
CEO and President and DirectorKevin SayerView All
Thematic Classification
Currently Active Investing Idea
  Medical Equipment
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Diagnostics & Research
InstrumentUSA Stock View All
RegionNorth America
LocationCalifornia; U.S.A
Business Address6340 Sequence Drive, San Diego, CA 92121, United States
ExchangeBATS Exchange
CIK Number0001093557
IndustryMedical Laboratories & Research
Phone858 200 0200
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestOctober 31, 2019
DexCom (DXCM) is traded on BATS Exchange in USA. It is located in 6340 Sequence Drive, San Diego, CA 92121, United States and employs 2,800 people. DexCom is listed under Medical Equipment category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 18.27 B. DexCom conducts business under Healthcare sector and is part of Medical Laboratories & Research industry. The entity has 91.53 M outstanding shares of which 5.47 M shares are currently shorted by private and institutional investors with about 8.72 trading days to cover. DEXCOM currently holds about 1.43 B in cash with (135.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.62.
Check DexCom Probability Of Bankruptcy

Ownership Allocation (%)

DexCom Target Price Odds Analysis

Odds Below 202.81HorizonTargetOdds Above 202.81
99.82%30 days 202.81 0.18%
Based on normal probability distribution, the odds of DexCom to move above current price in 30 days from now is near 1 (This DexCom probability density function shows the probability of DexCom Stock to fall within a particular range of prices over 30 days) .

DexCom Top Holders

DexCom Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares7.1 M1.1 B
Blackrock IncCommon Shares5.3 M791.9 M
View DexCom Diagnostics

DexCom Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

DexCom Key Fundamentals

DexCom Against Markets

Did you try this?

Run Price Transformation Now


Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

DexCom Upcoming and Recent Events

DexCom Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 20, 2020
Next Earnings ReportMay 6, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 20, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

DexCom Corporate Filings

DexCom SEC Reporting

Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition
Other Events. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Results of Operations and Financial Condition

DexCom Corporate Directors

Eric Topol Independent Director
Nicholas Augustinos Independent Director
Mark Foletta Independent Director
Additionally see Investing Opportunities. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.